Aimspro – yet another Multiple Sclerosis treatment


Aimspro shows great promise for the treatment of a range of neurological and inflammatory conditions including multiple sclerosis, CIDP and rheumatoid arthritis. Aimspro has been characterised biochemically and its mode of action has been determined. It comprises of a set of peptides that act to stimulate the release and regulation in the patient, of a molecular cascade that modulates the Hypothalamo-Pituitary-Adrenal (HPA) axis; a system found to be dysfunctional in some patients suffering from Multiple Sclerosis. In addition, Aimspro has powerful anti-inflammatory properties as it contains cytokines that induce a predominantly TH-2 anti-inflammatory profile in the patient thus relieving symptoms in a wide range of inflammatory conditions.

It has become apparent that some of the peptides in Aimspro are regulated and bound by specific carrier molecules that may regulate the action and release of their ligand and are probably necessary for the appropriate regulation and pharmacokinetics of the molecular machinery. The carrier molecules also function as a slow release mechanism, releasing bioactive components over several days.

Compared with conventional drugs, which generally comprise one molecule destined to interact with one target in the body, the unique molecular complexity of Aimspro enables it to interact with many molecular targets in concert, hence bringing about a wide range of physiological benefits.


Leave a Reply

Please log in using one of these methods to post your comment: Logo

You are commenting using your account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: